Copyright Reports & Markets. All rights reserved.

Global Human Plasma-based Hyperimmune Preparation Supply, Demand and Key Producers, 2023-2029

Request for Sample of this report
Buy now

1 Supply Summary

  • 1.1 Human Plasma-based Hyperimmune Preparation Introduction
  • 1.2 World Human Plasma-based Hyperimmune Preparation Supply & Forecast
    • 1.2.1 World Human Plasma-based Hyperimmune Preparation Production Value (2018 & 2022 & 2029)
    • 1.2.2 World Human Plasma-based Hyperimmune Preparation Production (2018-2029)
    • 1.2.3 World Human Plasma-based Hyperimmune Preparation Pricing Trends (2018-2029)
  • 1.3 World Human Plasma-based Hyperimmune Preparation Production by Region (Based on Production Site)
    • 1.3.1 World Human Plasma-based Hyperimmune Preparation Production Value by Region (2018-2029)
    • 1.3.2 World Human Plasma-based Hyperimmune Preparation Production by Region (2018-2029)
    • 1.3.3 World Human Plasma-based Hyperimmune Preparation Average Price by Region (2018-2029)
    • 1.3.4 North America Human Plasma-based Hyperimmune Preparation Production (2018-2029)
    • 1.3.5 Europe Human Plasma-based Hyperimmune Preparation Production (2018-2029)
    • 1.3.6 China Human Plasma-based Hyperimmune Preparation Production (2018-2029)
    • 1.3.7 Japan Human Plasma-based Hyperimmune Preparation Production (2018-2029)
  • 1.4 Market Drivers, Restraints and Trends
    • 1.4.1 Human Plasma-based Hyperimmune Preparation Market Drivers
    • 1.4.2 Factors Affecting Demand
    • 1.4.3 Human Plasma-based Hyperimmune Preparation Major Market Trends
  • 1.5 Influence of COVID-19 and Russia-Ukraine War
    • 1.5.1 Influence of COVID-19
    • 1.5.2 Influence of Russia-Ukraine War

2 Demand Summary

  • 2.1 World Human Plasma-based Hyperimmune Preparation Demand (2018-2029)
  • 2.2 World Human Plasma-based Hyperimmune Preparation Consumption by Region
    • 2.2.1 World Human Plasma-based Hyperimmune Preparation Consumption by Region (2018-2023)
    • 2.2.2 World Human Plasma-based Hyperimmune Preparation Consumption Forecast by Region (2024-2029)
  • 2.3 United States Human Plasma-based Hyperimmune Preparation Consumption (2018-2029)
  • 2.4 China Human Plasma-based Hyperimmune Preparation Consumption (2018-2029)
  • 2.5 Europe Human Plasma-based Hyperimmune Preparation Consumption (2018-2029)
  • 2.6 Japan Human Plasma-based Hyperimmune Preparation Consumption (2018-2029)
  • 2.7 South Korea Human Plasma-based Hyperimmune Preparation Consumption (2018-2029)
  • 2.8 ASEAN Human Plasma-based Hyperimmune Preparation Consumption (2018-2029)
  • 2.9 India Human Plasma-based Hyperimmune Preparation Consumption (2018-2029)

3 World Human Plasma-based Hyperimmune Preparation Manufacturers Competitive Analysis

  • 3.1 World Human Plasma-based Hyperimmune Preparation Production Value by Manufacturer (2018-2023)
  • 3.2 World Human Plasma-based Hyperimmune Preparation Production by Manufacturer (2018-2023)
  • 3.3 World Human Plasma-based Hyperimmune Preparation Average Price by Manufacturer (2018-2023)
  • 3.4 Human Plasma-based Hyperimmune Preparation Company Evaluation Quadrant
  • 3.5 Industry Rank and Concentration Rate (CR)
    • 3.5.1 Global Human Plasma-based Hyperimmune Preparation Industry Rank of Major Manufacturers
    • 3.5.2 Global Concentration Ratios (CR4) for Human Plasma-based Hyperimmune Preparation in 2022
    • 3.5.3 Global Concentration Ratios (CR8) for Human Plasma-based Hyperimmune Preparation in 2022
  • 3.6 Human Plasma-based Hyperimmune Preparation Market: Overall Company Footprint Analysis
    • 3.6.1 Human Plasma-based Hyperimmune Preparation Market: Region Footprint
    • 3.6.2 Human Plasma-based Hyperimmune Preparation Market: Company Product Type Footprint
    • 3.6.3 Human Plasma-based Hyperimmune Preparation Market: Company Product Application Footprint
  • 3.7 Competitive Environment
    • 3.7.1 Historical Structure of the Industry
    • 3.7.2 Barriers of Market Entry
    • 3.7.3 Factors of Competition
  • 3.8 New Entrant and Capacity Expansion Plans
  • 3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World

  • 4.1 United States VS China: Human Plasma-based Hyperimmune Preparation Production Value Comparison
    • 4.1.1 United States VS China: Human Plasma-based Hyperimmune Preparation Production Value Comparison (2018 & 2022 & 2029)
    • 4.1.2 United States VS China: Human Plasma-based Hyperimmune Preparation Production Value Market Share Comparison (2018 & 2022 & 2029)
  • 4.2 United States VS China: Human Plasma-based Hyperimmune Preparation Production Comparison
    • 4.2.1 United States VS China: Human Plasma-based Hyperimmune Preparation Production Comparison (2018 & 2022 & 2029)
    • 4.2.2 United States VS China: Human Plasma-based Hyperimmune Preparation Production Market Share Comparison (2018 & 2022 & 2029)
  • 4.3 United States VS China: Human Plasma-based Hyperimmune Preparation Consumption Comparison
    • 4.3.1 United States VS China: Human Plasma-based Hyperimmune Preparation Consumption Comparison (2018 & 2022 & 2029)
    • 4.3.2 United States VS China: Human Plasma-based Hyperimmune Preparation Consumption Market Share Comparison (2018 & 2022 & 2029)
  • 4.4 United States Based Human Plasma-based Hyperimmune Preparation Manufacturers and Market Share, 2018-2023
    • 4.4.1 United States Based Human Plasma-based Hyperimmune Preparation Manufacturers, Headquarters and Production Site (States, Country)
    • 4.4.2 United States Based Manufacturers Human Plasma-based Hyperimmune Preparation Production Value (2018-2023)
    • 4.4.3 United States Based Manufacturers Human Plasma-based Hyperimmune Preparation Production (2018-2023)
  • 4.5 China Based Human Plasma-based Hyperimmune Preparation Manufacturers and Market Share
    • 4.5.1 China Based Human Plasma-based Hyperimmune Preparation Manufacturers, Headquarters and Production Site (Province, Country)
    • 4.5.2 China Based Manufacturers Human Plasma-based Hyperimmune Preparation Production Value (2018-2023)
    • 4.5.3 China Based Manufacturers Human Plasma-based Hyperimmune Preparation Production (2018-2023)
  • 4.6 Rest of World Based Human Plasma-based Hyperimmune Preparation Manufacturers and Market Share, 2018-2023
    • 4.6.1 Rest of World Based Human Plasma-based Hyperimmune Preparation Manufacturers, Headquarters and Production Site (State, Country)
    • 4.6.2 Rest of World Based Manufacturers Human Plasma-based Hyperimmune Preparation Production Value (2018-2023)
    • 4.6.3 Rest of World Based Manufacturers Human Plasma-based Hyperimmune Preparation Production (2018-2023)

5 Market Analysis by Type

  • 5.1 World Human Plasma-based Hyperimmune Preparation Market Size Overview by Type: 2018 VS 2022 VS 2029
  • 5.2 Segment Introduction by Type
    • 5.2.1 Hepatitis B Immunoglobulins
    • 5.2.2 Rabies Immunoglobulins
    • 5.2.3 Tetanus Immunoglobulins
    • 5.2.4 Rho(D) Immunoglobulins
    • 5.2.5 Other
  • 5.3 Market Segment by Type
    • 5.3.1 World Human Plasma-based Hyperimmune Preparation Production by Type (2018-2029)
    • 5.3.2 World Human Plasma-based Hyperimmune Preparation Production Value by Type (2018-2029)
    • 5.3.3 World Human Plasma-based Hyperimmune Preparation Average Price by Type (2018-2029)

6 Market Analysis by Application

  • 6.1 World Human Plasma-based Hyperimmune Preparation Market Size Overview by Application: 2018 VS 2022 VS 2029
  • 6.2 Segment Introduction by Application
    • 6.2.1 Government Institution
    • 6.2.2 Private Sector
    • 6.2.3 Others
  • 6.3 Market Segment by Application
    • 6.3.1 World Human Plasma-based Hyperimmune Preparation Production by Application (2018-2029)
    • 6.3.2 World Human Plasma-based Hyperimmune Preparation Production Value by Application (2018-2029)
    • 6.3.3 World Human Plasma-based Hyperimmune Preparation Average Price by Application (2018-2029)

7 Company Profiles

  • 7.1 CSL Behring
    • 7.1.1 CSL Behring Details
    • 7.1.2 CSL Behring Major Business
    • 7.1.3 CSL Behring Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.1.4 CSL Behring Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.1.5 CSL Behring Recent Developments/Updates
    • 7.1.6 CSL Behring Competitive Strengths & Weaknesses
  • 7.2 Grifols
    • 7.2.1 Grifols Details
    • 7.2.2 Grifols Major Business
    • 7.2.3 Grifols Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.2.4 Grifols Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.2.5 Grifols Recent Developments/Updates
    • 7.2.6 Grifols Competitive Strengths & Weaknesses
  • 7.3 Biotest
    • 7.3.1 Biotest Details
    • 7.3.2 Biotest Major Business
    • 7.3.3 Biotest Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.3.4 Biotest Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.3.5 Biotest Recent Developments/Updates
    • 7.3.6 Biotest Competitive Strengths & Weaknesses
  • 7.4 Kedrion
    • 7.4.1 Kedrion Details
    • 7.4.2 Kedrion Major Business
    • 7.4.3 Kedrion Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.4.4 Kedrion Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.4.5 Kedrion Recent Developments/Updates
    • 7.4.6 Kedrion Competitive Strengths & Weaknesses
  • 7.5 CBPO
    • 7.5.1 CBPO Details
    • 7.5.2 CBPO Major Business
    • 7.5.3 CBPO Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.5.4 CBPO Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.5.5 CBPO Recent Developments/Updates
    • 7.5.6 CBPO Competitive Strengths & Weaknesses
  • 7.6 Emergent (Cangene)
    • 7.6.1 Emergent (Cangene) Details
    • 7.6.2 Emergent (Cangene) Major Business
    • 7.6.3 Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.6.4 Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.6.5 Emergent (Cangene) Recent Developments/Updates
    • 7.6.6 Emergent (Cangene) Competitive Strengths & Weaknesses
  • 7.7 Kamada
    • 7.7.1 Kamada Details
    • 7.7.2 Kamada Major Business
    • 7.7.3 Kamada Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.7.4 Kamada Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.7.5 Kamada Recent Developments/Updates
    • 7.7.6 Kamada Competitive Strengths & Weaknesses
  • 7.8 CNBG
    • 7.8.1 CNBG Details
    • 7.8.2 CNBG Major Business
    • 7.8.3 CNBG Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.8.4 CNBG Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.8.5 CNBG Recent Developments/Updates
    • 7.8.6 CNBG Competitive Strengths & Weaknesses
  • 7.9 Hualan Bio
    • 7.9.1 Hualan Bio Details
    • 7.9.2 Hualan Bio Major Business
    • 7.9.3 Hualan Bio Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.9.4 Hualan Bio Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.9.5 Hualan Bio Recent Developments/Updates
    • 7.9.6 Hualan Bio Competitive Strengths & Weaknesses
  • 7.10 Shanghai RAAS
    • 7.10.1 Shanghai RAAS Details
    • 7.10.2 Shanghai RAAS Major Business
    • 7.10.3 Shanghai RAAS Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.10.4 Shanghai RAAS Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.10.5 Shanghai RAAS Recent Developments/Updates
    • 7.10.6 Shanghai RAAS Competitive Strengths & Weaknesses
  • 7.11 Sichuan Yuanda Shuyang
    • 7.11.1 Sichuan Yuanda Shuyang Details
    • 7.11.2 Sichuan Yuanda Shuyang Major Business
    • 7.11.3 Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.11.4 Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
    • 7.11.6 Sichuan Yuanda Shuyang Competitive Strengths & Weaknesses
  • 7.12 ADMA Biologics
    • 7.12.1 ADMA Biologics Details
    • 7.12.2 ADMA Biologics Major Business
    • 7.12.3 ADMA Biologics Human Plasma-based Hyperimmune Preparation Product and Services
    • 7.12.4 ADMA Biologics Human Plasma-based Hyperimmune Preparation Production, Price, Value, Gross Margin and Market Share (2018-2023)
    • 7.12.5 ADMA Biologics Recent Developments/Updates
    • 7.12.6 ADMA Biologics Competitive Strengths & Weaknesses

8 Industry Chain Analysis

  • 8.1 Human Plasma-based Hyperimmune Preparation Industry Chain
  • 8.2 Human Plasma-based Hyperimmune Preparation Upstream Analysis
    • 8.2.1 Human Plasma-based Hyperimmune Preparation Core Raw Materials
    • 8.2.2 Main Manufacturers of Human Plasma-based Hyperimmune Preparation Core Raw Materials
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis
  • 8.5 Human Plasma-based Hyperimmune Preparation Production Mode
  • 8.6 Human Plasma-based Hyperimmune Preparation Procurement Model
  • 8.7 Human Plasma-based Hyperimmune Preparation Industry Sales Model and Sales Channels
    • 8.7.1 Human Plasma-based Hyperimmune Preparation Sales Model
    • 8.7.2 Human Plasma-based Hyperimmune Preparation Typical Customers

9 Research Findings and Conclusion

    10 Appendix

    • 10.1 Methodology
    • 10.2 Research Process and Data Source

    The global Human Plasma-based Hyperimmune Preparation market size is expected to reach $ 2866.8 million by 2029, rising at a market growth of 5.9% CAGR during the forecast period (2023-2029).
    Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
    This report studies the global Human Plasma-based Hyperimmune Preparation production, demand, key manufacturers, and key regions.
    This report is a detailed and comprehensive analysis of the world market for Human Plasma-based Hyperimmune Preparation, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Human Plasma-based Hyperimmune Preparation that contribute to its increasing demand across many markets.
    Highlights and key features of the study
    Global Human Plasma-based Hyperimmune Preparation total production and demand, 2018-2029, (K Units)
    Global Human Plasma-based Hyperimmune Preparation total production value, 2018-2029, (USD Million)
    Global Human Plasma-based Hyperimmune Preparation production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
    Global Human Plasma-based Hyperimmune Preparation consumption by region & country, CAGR, 2018-2029 & (K Units)
    U.S. VS China: Human Plasma-based Hyperimmune Preparation domestic production, consumption, key domestic manufacturers and share
    Global Human Plasma-based Hyperimmune Preparation production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
    Global Human Plasma-based Hyperimmune Preparation production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
    Global Human Plasma-based Hyperimmune Preparation production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
    This reports profiles key players in the global Human Plasma-based Hyperimmune Preparation market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG and Hualan Bio, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Human Plasma-based Hyperimmune Preparation market
    Detailed Segmentation:
    Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
    Global Human Plasma-based Hyperimmune Preparation Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World
    Global Human Plasma-based Hyperimmune Preparation Market, Segmentation by Type
    Hepatitis B Immunoglobulins
    Rabies Immunoglobulins
    Tetanus Immunoglobulins
    Rho(D) Immunoglobulins
    Other
    Global Human Plasma-based Hyperimmune Preparation Market, Segmentation by Application
    Government Institution
    Private Sector
    Others
    Companies Profiled:
    CSL Behring
    Grifols
    Biotest
    Kedrion
    CBPO
    Emergent (Cangene)
    Kamada
    CNBG
    Hualan Bio
    Shanghai RAAS
    Sichuan Yuanda Shuyang
    ADMA Biologics
    Key Questions Answered
    1. How big is the global Human Plasma-based Hyperimmune Preparation market?
    2. What is the demand of the global Human Plasma-based Hyperimmune Preparation market?
    3. What is the year over year growth of the global Human Plasma-based Hyperimmune Preparation market?
    4. What is the production and production value of the global Human Plasma-based Hyperimmune Preparation market?
    5. Who are the key producers in the global Human Plasma-based Hyperimmune Preparation market?
    6. What are the growth factors driving the market demand?

    Buy now